WO2012157984A3 - 신규한 헤테로방향족 화합물 및 이의 용도 - Google Patents

신규한 헤테로방향족 화합물 및 이의 용도 Download PDF

Info

Publication number
WO2012157984A3
WO2012157984A3 PCT/KR2012/003912 KR2012003912W WO2012157984A3 WO 2012157984 A3 WO2012157984 A3 WO 2012157984A3 KR 2012003912 W KR2012003912 W KR 2012003912W WO 2012157984 A3 WO2012157984 A3 WO 2012157984A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
present
coxsackievirus
heteroaromatic compounds
novel heteroaromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/003912
Other languages
English (en)
French (fr)
Other versions
WO2012157984A2 (ko
Inventor
김용철
김보경
조중희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gwangju Institute of Science and Technology
Original Assignee
Gwangju Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gwangju Institute of Science and Technology filed Critical Gwangju Institute of Science and Technology
Publication of WO2012157984A2 publication Critical patent/WO2012157984A2/ko
Publication of WO2012157984A3 publication Critical patent/WO2012157984A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 신규한 헤테로방향성 유도체 화합물 및 이를 이용한 콕사키바이러스 감염으로 인한 질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명의 조성물은 콕사키바이러스의 증식에 관련되는 효소에 높은 친화력으로 결합하여 바이러스의 증식 및 활성을 효율적으로 억제함으로써 콕사키바이러스 감염으로 인한 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
PCT/KR2012/003912 2011-05-19 2012-05-17 신규한 헤테로방향족 화합물 및 이의 용도 Ceased WO2012157984A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0047349 2011-05-19
KR1020110047349A KR101348900B1 (ko) 2011-05-19 2011-05-19 신규한 헤테로방향족 화합물 및 이의 용도

Publications (2)

Publication Number Publication Date
WO2012157984A2 WO2012157984A2 (ko) 2012-11-22
WO2012157984A3 true WO2012157984A3 (ko) 2013-03-21

Family

ID=47177505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/003912 Ceased WO2012157984A2 (ko) 2011-05-19 2012-05-17 신규한 헤테로방향족 화합물 및 이의 용도

Country Status (2)

Country Link
KR (1) KR101348900B1 (ko)
WO (1) WO2012157984A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891699B1 (ko) * 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US20100298209A1 (en) * 2007-11-02 2010-11-25 Estaquier Jerome Compounds for preventing or treating a viral infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891699B1 (ko) * 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((ｓ)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US20100298209A1 (en) * 2007-11-02 2010-11-25 Estaquier Jerome Compounds for preventing or treating a viral infection

Also Published As

Publication number Publication date
KR101348900B1 (ko) 2014-01-07
WO2012157984A2 (ko) 2012-11-22
KR20120129227A (ko) 2012-11-28

Similar Documents

Publication Publication Date Title
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
WO2011158039A8 (en) Ureido-pyrazole derivatives for use in the treatment of respiratory syncitial virus (rsv) infection
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
WO2011106106A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
WO2012062925A3 (en) Compounds and methods for treating pain
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
PH12013501750A1 (en) Guanidine compound
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
MY182771A (en) Viral replication inhibitors
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
MX2014010563A (es) Benzodioxanos en combinacion con otros activos para inhibir la produccion de leucotrieno.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
WO2012036573A3 (en) Compounds as modulators of a mutant cftr protein and their use for treating diseases associated with cftr protein malfunction
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
CA2881554C (en) Methods for inhibiting fascin
WO2010032011A3 (en) Anti-fungal therapy
WO2014060493A3 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
WO2010052559A8 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12786451

Country of ref document: EP

Kind code of ref document: A2